Want to see JP:4592 full AI Analyst Report?
4592 Stock Chart & Stats
¥2230.00
¥19.00(2.53%)
At close: 4:00 PM EST
¥2230.00
¥19.00(2.53%)
Day’s Range― - ―
52-Week Range¥914.00 - ¥3,990.00
Previous CloseN/A
Volume765.40K
Average Volume (3M)2.08M
Market Cap
¥77.90B
Enterprise Value¥68.34B
Total Cash (Recent Filing)¥2.74B
Total Debt (Recent Filing)¥1.36B
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Sep 10, 2026EPS Estimate
-4.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-50.61
Shares Outstanding78,058,880
10 Day Avg. Volume2,869,570
30 Day Avg. Volume2,080,090
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)9.94
Price to Sales (P/S)0.00
P/FCF Ratio-35.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,575.00Price Target Upside-29.37% Downside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-50.85
Revenue Forecast (FY)¥1.74B
Bulls Say, Bears Say
Bulls Say
Proprietary Cell Therapy PlatformOwning a proprietary cell-based platform targeting neurological and other serious diseases creates durable R&D leverage. A platform approach can support multiple indications, raise entry barriers vs peers, and enable long-term value via sequential programs or partner/licensing deals if clinical proof is achieved.
Improved Balance Sheet SolvencyA materially larger equity base and expanded assets improve reported solvency and provide a longer notional runway. Manageable leverage in recent years (debt-to-equity ~0.21–0.24 for 2023–2025) reduces immediate default risk and supports ability to fund near-term clinical programs without immediate distress.
Operational Cash-burn ImprovementProgress toward lower operating outflows signals better cost control or higher program efficiency. While still negative, reduced burn rates lengthen financing intervals, lower short-term refinancing frequency, and indicate management may be improving resource allocation across development-stage programs.
Bears Say
No Commercial RevenueAbsence of any product revenue means the company remains entirely dependent on development outcomes and external financing. Long-term viability and ability to scale depend on successful clinical results and commercialization, making fundamentals highly binary and outcome-driven over the coming months to years.
Sustained Heavy Cash BurnPersistent multi-year negative operating and free cash flows erode reserves and necessitate repeated capital raises. This structural cash-burn increases dilution risk for shareholders, constrains discretionary R&D investment, and makes long-term program continuity contingent on successful financing or partnerships.
Funding And Leverage VulnerabilityHistoric volatility in leverage and consistently negative returns on equity indicate funding sensitivity. A reliance on external capital creates timing and refinancing risk, which can force unfavorable financing terms, slow program execution, or dilute ownership if clinical progress does not attract non-dilutive funding.
SanBio Co News
4592 FAQ
What was SanBio Co Ltd’s price range in the past 12 months?
SanBio Co Ltd lowest stock price was ¥914.00 and its highest was ¥3990.00 in the past 12 months.
What is SanBio Co Ltd’s market cap?
SanBio Co Ltd’s market cap is ¥77.90B.
When is SanBio Co Ltd’s upcoming earnings report date?
SanBio Co Ltd’s upcoming earnings report date is Sep 10, 2026 which is in 71 days.
How were SanBio Co Ltd’s earnings last quarter?
SanBio Co Ltd released its earnings results on Jun 15, 2026. The company reported -¥10.71 earnings per share for the quarter, missing the consensus estimate of -¥6.194 by -¥4.516.
Is SanBio Co Ltd overvalued?
According to Wall Street analysts SanBio Co Ltd’s price is currently Overvalued.
Does SanBio Co Ltd pay dividends?
SanBio Co Ltd does not currently pay dividends.
What is SanBio Co Ltd’s EPS estimate?
SanBio Co Ltd’s EPS estimate is -4.8.
How many shares outstanding does SanBio Co Ltd have?
SanBio Co Ltd has 78,058,880 shares outstanding.
What happened to SanBio Co Ltd’s price movement after its last earnings report?
SanBio Co Ltd reported an EPS of -¥10.71 in its last earnings report, missing expectations of -¥6.194. Following the earnings report the stock price went up 0.749%.
Which hedge fund is a major shareholder of SanBio Co Ltd?
Currently, no hedge funds are holding shares in JP:4592
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SanBio Co Ltd
SanBio Company Limited is dedicated to the creation, production, and sale of regenerative cell therapies, primarily concentrated on disorders of the central nervous system. A central component of their portfolio is SB623, a treatment that has completed Phase 2 clinical trials in both the United States and Japan for traumatic brain injury. Beyond this, their comprehensive research pipeline explores the broader potential of SB623 for conditions such as ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, and Alzheimer's disease. The company's development efforts also encompass other innovative treatments: SB618 for peripheral nerve damage, SB308 for muscular dystrophy, MSC1 for cancer, and MSC2 for inflammatory diseases and optic neuritis. Founded in 2001, SanBio maintains its corporate headquarters in Tokyo, Japan.
4592 Company Deck
4592 Earnings Call
Q4 2026
0:00 / 0:00
4592 Stock 12 Month Forecast
Average Price Target
¥1,575.00
▼(-29.37% Downside)
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---